Health Care
Price
$47.80
+1.81%Market Cap
$68.04B
Day High
$48.06
Day Low
$46.83
Boston Scientific posted 7.5% revenue growth and a 70.7% gross margin in Q2 FY2026, propelled by its Cardiovascular segment, while aggressive capital deployment and a major pending acquisition highlight both opportunity and risk.
Key risk: Integration of Large Acquisitions
The pending $14.5 billion acquisition of Penumbra presents significant integration, execution, and financial risks. Financing the transaction will require $11 billion in new debt and cash, which could strain the balance sheet and distract management. Delays in regulatory approval or failure to achieve expected synergies could materially impact results.
Other Health Care Equipment companies